Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Tomoya Kagawa"'
Publikováno v:
Kidney International Reports. 8:115-125
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6e938458ace811ab75bd8b4f2d41657
https://doi.org/10.1016/j.ekir.2022.10.006
https://doi.org/10.1016/j.ekir.2022.10.006
Autor:
Masanori Watanabe, Osamu Matsuoka, Yusuke Moritoh, Tomoya Kagawa, Harunobu Nishizaki, Akihiro Kobayashi
Publikováno v:
Diabetes
SCO-267 is a full agonist of the free fatty acid receptor 1 (GPR40), which regulates the secretion of islet and gut hormones. In this phase 1 study, we aimed to evaluate the clinical profile of single and multiple once-daily oral administration of SC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c62e48f0f0bdb259a5bf3833ed0e96fc
https://europepmc.org/articles/PMC8978616/
https://europepmc.org/articles/PMC8978616/
Autor:
Masanori Watanabe, Harunobu Nishizaki, Yusuke Moritoh, Tomoya Kagawa, Akihiro Kobayashi, Osamu Matsuoka
SCO-267 is a full agonist of the free fatty acid receptor 1 (GPR40), which regulates the secretion of islet and gut hormones. In this phase 1 study, we aimed to evaluate the clinical profile of single and multiple once-daily oral administration of SC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dcc31ce677958549ad0e69731a8a293
https://doi.org/10.2337/figshare.15036009.v1
https://doi.org/10.2337/figshare.15036009.v1
Autor:
Osamu Matsuoka, Meguru Achira, Masanori Watanabe, Tomoya Kagawa, Yusuke Moritoh, Harunobu Nishizaki
Publikováno v:
Diabetes. 70
The clinical potential of SCO-267, an orally available allosteric full agonist against GPR40 that regulates islet and gut hormone secretion, is largely unknown. Here, we present the first clinical study using the GPR40 full agonist. A randomized, sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a7904203449577b3f6385abd1ea0896
https://doi.org/10.2337/db21-751-p
https://doi.org/10.2337/db21-751-p
Autor:
Tomoya Kagawa, Tokurou Kobayashi, Shingo Kuroda, Masashi Sakaki, Yuhei Sano, Takuya Saiki, Emiko Koumura, Yukio Shimasaki, Kohei Shimizu, Minoru Itou, Kumi Matsuno, Masako Aso
Publikováno v:
Clinical Drug Investigation. 38:1041-1051
Imarikiren hydrochloride (TAK-272; SCO-272) is a novel direct renin inhibitor. The objective of this study was to determine the effects of renal impairment (RI) or hepatic impairment (HI) on the pharmacokinetics and safety of imarikiren. This phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b77f19a2428e8c570a727f805ba5f8b2
https://doi.org/10.1007/s40261-018-0695-4
https://doi.org/10.1007/s40261-018-0695-4
Autor:
Kumi Matsuno, Takamasa Hashimoto, Shingo Tanaka, Tomoya Kagawa, Emiko Koumura, Hiroyuki Nakamichi
Publikováno v:
Journal of Clinical Pharmacology
Imarikiren hydrochloride (TAK‐272/ SCO‐272) is a novel direct renin inhibitor. This randomized, double‐blind, phase I study evaluated the safety and pharmacokinetics/pharmacodynamics of multiple oral administrations of imarikiren in healthy non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3456d1f5418bff6627cd74602cb51e90
https://doi.org/10.1002/jcph.1142
https://doi.org/10.1002/jcph.1142
Autor:
Shingo Kuroda, Yuusuke Umeda, Sadayoshi Ito, Yuhei Sano, Tomoya Kagawa, Kohei Shimizu, Takuya Saiki
BACKGROUND AND OBJECTIVES: Imarikiren is a novel, potent, and selective direct renin inhibitor that has shown high oral availability during clinical development for the treatment of diabetic nephropathy. We evaluated the efficacy and safety of imarik
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14f752a7da015c944b7b6ee24e9d9d0b
https://europepmc.org/articles/PMC6419291/
https://europepmc.org/articles/PMC6419291/
Publikováno v:
Basicclinical pharmacologytoxicology. 123(5)
Imarikiren hydrochloride (TAK-272/SCO-272) is a novel direct renin inhibitor with potential indications for cardiovascular and renal diseases. This phase I study evaluated the pharmacokinetics, pharmacodynamics and safety of a single oral administrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc393f6684afc43ac6a992cb202a0f40
https://pubmed.ncbi.nlm.nih.gov/29845723
https://pubmed.ncbi.nlm.nih.gov/29845723
Publikováno v:
Cardiovascular Therapeutics
Summary Background Low-density lipoproteins (LDLs) comprise a heterogeneous group of particles with various size and density. A shift to larger LDL particle size is mainly the result of a decrease in small dense LDL (sd-LDL) levels and an increase in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3d04d5b9f7ed9099fd183dedf715f84
https://doi.org/10.1111/1755-5922.12146
https://doi.org/10.1111/1755-5922.12146
Publikováno v:
Clinical Therapeutics. 36:711-721
Guidelines for the management of hypertension recommend using drugs with different mechanisms of action in antihypertensive regimens that include simple single-pill fixed-dose combination (FDC) products.The objective of this study was to compare the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab5431e45cbed26f20e8a388af2a93a5
https://doi.org/10.1016/j.clinthera.2014.03.009
https://doi.org/10.1016/j.clinthera.2014.03.009